CARTISTEM® Surgery
The simple, effective surgical procedure for the regeneration of cartilage, which is performed at the Spectrum Surgical Center in Nassau in their two operating theaters.
Since 2012, 35,000 patients with knee osteoarthritis patients have regained pain-free mobility with CARTISTEM®.
Surgical Procedure
CARTISTEM® which is a bio-pharmacochemical drug from allogeneic human Umbilical Cord Blood-derived Mesenchymal stem cells (MSCs) known as hUCB-MSCs hUCB-MSCs combined with Hippuric acid is a surgical treatment as an alternative to artificial knee-replacement surgery.
Approved product-label by the Korean Regulatory Authority (MFDS) CARTISTEM® reads:
“CARTISTEM® is indicated for the treatment of articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma for anyone over the age of 18 years.”
Testimonial
Testimonial of Guus Hiddink a world famous football manager treated with CARTISTEM® for OA knee in South Korea in 2014.
In 2023, it was estimated that 1 million total knee replacements (TKRs) were performed in the US and, with an ever-aging population, a projected estimate of 3.5 million will be done per year by 2030. TKRs are the only currently approved treatment for osteoarthritis of the knee due to degeneration of knee cartilage or repeated trauma. However, a recent study published in Lancet Medical Journal with publication link below showed that the median time to revision for patients who underwent a TKR surgery younger than 60 years of age was 4.4 years.
Read Study published in Lancet Medical Journal.
CARTISTEM® is a ground-breaking treatment for patients with osteoarthritis of the knee as a result of degenerative disease or trauma — CARTISTEM® is the viable alternative to a total or partial knee replacement.
Following recovery from the anaesthetic, the patient rests overnight with the leg held in an extended position by a knee-brace. After surgery, the patient is mobile but must avoid weight-bearing for 4 – 8 weeks or as advised by the surgeon to allow for healing and natural regeneration of the patient’s own cartilage.
Clinical Trial Publication of CARTISTEM®
Allogeneic Umbilical Cord Blood–Derived Mesenchymal Stem Cell Implantation Versus Microfracture for Large, Full-Thickness Cartilage Defects in Older Patients (shows about 97% regeneration of knee cartilage)
A Multicenter Randomized Clinical Trial and Extended 5-Year Clinical Follow-up